Real-World Prevalence of Germline Mutations Associated with Homologous Recombination Deficiency in Patients with Biliary Tract Cancer

March 2022, Vol 3, No 1

Mutations associated with homologous recombination deficiency (HRD) have been identified in up to 25% of patients with biliary tract cancers; however, the proportion of patients with germline versus somatic mutations has not been previously defined.

In this retrospective, real-world study, Robin Kate Kelley, MD, University of California, San Francisco, and colleagues sought to determine the prevalence of germline and somatic mutations associated with HRD in a large population of patients with biliary tract cancer, and the association of these mutations with key clinical parameters.

Dr Kelley presented the results at the 2022 ASCO GI Cancers Symposium.

In this retrospective analysis, the investigators identified records of patients with biliary tract cancer who underwent next-generation sequencing between 2017 and 2021.

The analyses focused on pathogenic or likely pathogenic somatic mutations and copy number variants, as well as incidental germline mutations limited to single nucleotide variants and small indels in 50 hereditary cancer genes. HRD-associated germline and somatic mutations were analyzed across 9 and 18 HRR pathway genes, respectively.

A total of 804 patients with biliary tract cancer (median age, 66 years; 55% were female) were included in the analysis; of these, 499 had intrahepatic cholangiocarcinoma (CCA), 83 had extrahepatic CCA, and 222 had gallbladder cancer.

Overall, the prevalence of germline mutations was 4.6%. By subtype, the prevalence of germline mutations was 5% in intrahepatic CCA, 4.8% in extrahepatic CCA, and 3.6% in gallbladder cancer. By age, the prevalence was 6.1% in patients under age 50 years at diagnosis and 4.5% in patients aged ≥50 years.

In all, 3.2% of patients had HRD-associated germline mutations versus 13% of patients with somatic mutations or with copy number variants.

A significant (P = .002) variation in HRD-associated mutations was seen across CCA subtypes, including 19% in gallbladder cancer, 10% in intrahepatic CCA, and 14% in extrahepatic CCA.

By gene alteration, HRD-associated germline mutations included 8 mutations in the ATM gene, 6 mutations in BRCA2, and 5 mutations in BRCA1; microsatellite instability was present in 1.4% of samples.

Based on these real-world data, a significant proportion of patients with biliary tract cancers harbor potentially clinically relevant HRD-associated germline or somatic mutations, according to Dr Kelley and colleagues.

Source

Kelley RK, Ashok A, Mauer E, et al. Prevalence of germline mutations and homologous recombination deficiency (HRD) in a real-world biliary tract cancer (BTC) cohort. Abstract 476.

Related Items

Characterization of Long-Term Survivors in TOPAZ-1
March 2023, Vol 4, No 1
Researchers examined the characteristics, outcomes, and genomic profiles of patients with advanced biliary tract cancer who were treated with durvalumab plus gemcitabine/cisplatin and experienced long-term survival.
MDM2-p53 Antagonist BI 907828 Demonstrated Promising Activity in Patients with Advanced BTC
March 2023, Vol 4, No 1
The novel MDM2-p53 antagonist BI 907828 is being investigated as a first-line treatment in patients with advanced biliary tract cancer.
Treatment and Survival Outcomes with Systemic Therapy for Patients with BTC with IDH1 Mutations: A Retrospective Study
March 2023, Vol 4, No 1
Long-term outcomes were evaluated in patients with IDH1-mutated biliary tract cancer who were treated with systemic therapy.
Phase 2 Study of CTX-009 plus Paclitaxel in Patients with Advanced BTC
March 2023, Vol 4, No 1
CTX-009 plus paclitaxel showed promising efficacy as second- or third-line treatment in patients with advanced biliary tract cancer.
Gunagratinib in Patients with Previously Treated Advanced CCA Harboring FGFR2 Fusions or Rearrangements
March 2023, Vol 4, No 1
Gunagratinib showed promising efficacy as a second-generation FGFR inhibitor and demonstrated potential to treat multiple FGFR pathway abnormalities.
Results from SWOG 1815: GemCis and Nab-Paclitaxel versus GemCis in Advanced BTC
March 2023, Vol 4, No 1
The SWOG 1815 trial found that treatment with gemcitabine/cisplatin and paclitaxel (GAP) did not result in a significant improvement in survival compared with gemcitabine and cisplatin in patients with advanced biliary tract cancer, though GAP may be beneficial in patients with locally advanced disease and GBC.
JCOG1202 Subgroup Analysis: Risk Factors for Early Relapse in Patients Undergoing Curative Resection
March 2023, Vol 4, No 1
A study of patients with resected biliary tract cancer (BTC) found that postoperative CA 19-9 level, tumor differentiation, lymph node metastases, and residual tumor significantly impact early relapse in patients with curatively resected BTC. Similar risk factors were also found in patients receiving adjuvant S-1.
Impact of Gene Expression in 5-FU Metabolic Pathways on Outcomes in Patients Enrolled in JCOG1202
March 2023, Vol 4, No 1
Results from a study evaluating the impact of 5-FU metabolic pathway enzyme expression on outcomes of patients with curatively resected biliary tract cancer showed that relapse-free survival was improved in patients with certain enzymes who received adjuvant S-1.
Atezolizumab with or without Bevacizumab in Combination with GemCis in Advanced BTC: Results from IMbrave 151
March 2023, Vol 4, No 1
Researchers assessed whether VEGF blockade plus chemotherapy with gemcitabine/cisplatin can enhance responses to PD-L1 inhibition by promoting an immune-permissive tumor microenvironment in patients with advanced biliary tract cancer.
Nab-Paclitaxel plus Sintilimab as Second-Line Treatment for Advanced BTC
March 2023, Vol 4, No 1
The safety and efficacy of second-line nab-paclitaxel combined with the anti-PD-1 antibody sintilimab was studied in patients with advanced biliary tract cancer.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: